« Back
Home /
Danegaptide

Danegaptide

Item no.	HY-10913-5mg
Manufacturer	MedChem Express
CASRN	943134-39-2
Amount	5mg
Quantity options	100 mg 10mg 1 ea 50mg 5mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Citations	[1]John A Butera, et al. Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation. J Med Chem. 2009 Feb 26;52(4):908-11.<br>[2]Elke De Vuyst, et al. Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. Br J Pharmacol. 2011 Jun;163(3):469-83.
Smiles	O=C(N[C@H]1CN(C(CN)=O)[C@H](C(O)=O)C1)C2=CC=CC=C2
ECLASS 5.1	30220300
ECLASS 6.1	30220300
ECLASS 8.0	32160605
ECLASS 9.0	32160605
ECLASS 10.0.1	32160490
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GAP-134; ZP 1609
Available
Product Description	Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect[1][2].
Shipping	Room temperature
Manufacturers Applications	Neuroscience-Neuromodulation
MolecularWeight	291.30
Clinical_Information	Phase 2
Manufacturers Research Area	Cardiovascular Disease
Solubility	10 mM in DMSO
Manufacturers Target	Gap Junction Protein
Pathway	Cytoskeleton

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5mg

available

Request delivery time